Why the study?
Heart failure with preserved ejection fraction is the most common and difficult-to-treat heart failure type, with therapeutic studies yielding uncertain results.
This review summarizes current knowledge on the diagnosis, phenotypes, and therapeutic challenges of heart failure with preserved ejection fraction.
HFpEF phenotyping may guide individualized care; leaves open validation in prospective trials.
Heart failure with preserved ejection fraction (HFpEF) is the most common type of heart failure (HF) - predominantly in the elderly population - and the most difficult to treat. The diagnosis is based, apart from clinical data, on data provided by imaging and biochemical evaluation: left ventricular (LV) diastolic dysfunction, EF ≥50% and increase of natriuretic peptide (NP). Several phenotypes of HFpEF have been identified based on etiological and pathophysiological data. Defining the phenotypes has allowed a wider knowledge of specific pathogenic mechanisms and conducting therapeutic studies with pharmacological and non-pharmacological agents . but with uncertain results. The diagnosis is based, apart from clinical data, on data provided by imaging and biochemical evaluation: left ventricular (LV) diastolic dysfunction, EF ≥50% and increase of natriuretic peptide (NP). Several phenotypes of HFpEF have been identified based on etiological and pathophysiological data. Defining the phenotypes has allowed a wider knowledge of specific pathogenic mechanisms and conducting therapeutic studies with pharmacological and non-pharmacological agents . but with uncertain results.
No takes yet. Share an insight, caveat, or question.
L Gherasim (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: